Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences President and CEO Derek J. Maetzold sold 4,017 shares of common stock across three transactions in early February 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Derek J. Maetzold, President & CEO and Director of Castle Biosciences, Inc. (CSTL), reported sales of common stock.
• A total of 4,017 shares were sold across three transactions on February 3 and February 4, 2026.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2025.
• On February 3, 2026, 3,200 shares were sold at a weighted-average price of $39.913 per share.
• On February 4, 2026, 646 shares were sold at a weighted-average price of $37.822 per share.
• Also on February 4, 2026, an additional 171 shares were sold at a weighted-average price of $38.61 per share.
• Following these transactions, Mr. Maetzold directly owns 83,698 shares of common stock.
• He also indirectly beneficially owns 261,372 shares through various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, the pre-arranged 10b5-1 plan mitigates concerns about immediate negative sentiment, indicating a planned financial action rather than a reaction to new company-specific news.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 plan, indicating a planned divestment rather than a reaction to new, negative information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned via a 10b5-1 plan, are common for executives managing personal finances and diversifying portfolios. In the biotechnology sector, such sales are generally not seen as a strong indicator of company performance unless they are unusually large or outside of a pre-established plan.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice across industries, including biotechnology, for executives to liquidate shares in a compliant manner. There are no specific comparable companies or projects mentioned in this Form 4 to benchmark against.

Related Party Transactions

• Indirect beneficial ownership is reported through various trusts (e.g., The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trusts, DJM Grantor Retained Annuity Trusts) involving the reporting person's spouse and children as beneficiaries, and the reporting person often serving as trustee. These are typical arrangements for executive compensation and estate planning.

Stakeholder Impact

• Shareholders: May perceive a slight negative signal from insider selling, though this is largely mitigated by the pre-arranged 10b5-1 plan. The overall impact is likely minimal given the relatively small number of shares sold compared to total holdings.

Key Dates

Recommendation

The insider sales by the CEO were conducted under a pre-arranged 10b5-1 plan, which suggests a planned financial action rather than a reaction to new, adverse company information. While insider selling can sometimes be a negative signal, the context of a 10b5-1 plan typically renders it a neutral event for investment decisions. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new fundamental information to alter an existing investment thesis.

Keywords

Castle Biosciences, CSTL, Derek Maetzold, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Healthcare